In response to the COVID-19 situation, OCLI is following enhanced safety protocols consistent with guidelines put forth by the CDC and the World Health Organization (WHO) to protect our patients and colleagues. Click here to learn about how we are keeping you safe.

AcrySof Phakic IOLs Receive European Approval

September 18, 2008

Alcon introduced its new Phakic IntraOcular Lens at this week’s European Society of Cataract and Refractive Surgery in Berlin.  This lens is an anterior chamber IOL that sits in front of the iris.  It is used to treat nearsightedness.  It offers the advantage of being a reversible procedure and having the ability to treat many patients who have been deemed poor LASIK candidates.  It can also treat patients who require stronger prescriptions than can be treated with LASIK.  This lens is only available overseas at this time as it is awaiting FDA approval.

 

The Acrysof Phakic Lens joins two other Phakic IOLs that already have FDA approval:

  • Verisyse® Phakic IOL sits in the front of the eye and is attached to the iris.

 

OCLI has been implanting both Phakic IOLs since their FDA approval several years ago.  Results have been excellent, with generally an improvement of vision as compared to vision with glasses before the surgery.  With the impending FDA approval of the new Acrysof, we anticipate adding this new lens to our refractive strategies.

Back to our blog

Services offered at OCLI

Our world-class team of professionals at OCLI can help you with the latest treatment options for you.

Request an appointment

* required